MAIA Biotech CEO Buys Big on Options, Signals Bullish Outlook Amid Phase‑2 Trial Hype
Insider option buys by MAIA Biotech executives signal confidence in its ateganosine trial and a potential upside in a low‑valued biotech stock.
3 minutes to read
MAIA BIOTECHNOLOGY INC
CEO Vitoc Vlad Buys 72,700 MAIA Shares Amid Thrilling THIO‑104 Breakthroughs and Executive Confidence Surge
CEO Vitoc Vlad’s recent 72,700‑share purchase at $1.39 signals bullish confidence in MAIA Biotechnology after early Phase‑3 THIO‑104 data, hinting at potential upside if the trial meets its endpoints.
3 minutes to read